However, there is a lack of available MDM2-p53 axis-targeted drugs for HCC patients [34], possibly attributed to the comparatively lower sensitivity of the liver to MDM2 alterations [17, 18]. This evidence concerns the gene TP53 and hepatocellular carcinoma.